Key result
Patients with Duchenne muscular dystrophy in Sweden had a median survival of 29.9 years, with 20.1% of deaths resulting from non-cardiopulmonary causes which occurred at significantly younger ages.
Why the study?
With increasing life expectancy in Duchenne muscular dystrophy from late teens to over 30 years of age, nationwide data on prevalence, life expectancy, and leading causes of death were needed.
Cohort (n=373)
Yes
In patients with Duchenne muscular dystrophy, median survival has reached 29.9 years, with 20% of deaths attributed to non-cardiopulmonary causes which occur at significantly younger ages than cardiopulmonary deaths.
No takes yet. Share an insight, caveat, or question.
Alerts clinicians to non-cardiopulmonary mortality risks in DMD; leaves open causal pathways and preventive strategies.
Wahlgren et al. (2021) conducted a cohort in Duchenne muscular dystrophy (n=373). Duchenne muscular dystrophy was evaluated on Median survival (95% CI 27.1-31.2). Patients with Duchenne muscular dystrophy in Sweden had a median survival of 29.9 years, with 20.1% of deaths resulting from non-cardiopulmonary causes which occurred at significantly younger ages.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: